Rifapentine and isoniazid for 12 weeks clinical trials
Rifapentine and isoniazid for 12 weeks is named as an intervention in 2 current clinical trials in our India, Canada and Australia registers. 1 is recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is The Aurum Institute NPC (1). The most-studied condition is HIV Seropositivity.
Patient leaflets for Rifapentine and isoniazid for 12 weeks
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Rifapentine and isoniazid for 12 weeks
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT03474029 · ClinicalTrials.gov ↗ · Latent Tuberculosis
|
Phase 2/3 | Recruiting | Centers for Disease Control and Prevention | Canada, Australia |
|
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
NCT05118490 · ClinicalTrials.gov ↗ · HIV Seropositivity, Tuberculosis, Household Contact
|
Phase 4 | Active, closed | The Aurum Institute NPC | India |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Rifapentine and isoniazid for 12 weeks
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| The Aurum Institute NPC | 1 |
| Centers for Disease Control and Prevention | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 1 | 0 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Rifapentine and isoniazid for 12 weeks trials
How many clinical trials are testing Rifapentine and isoniazid for 12 weeks?
2 current trials in our India, Canada and Australia registers name Rifapentine and isoniazid for 12 weeks as a drug or biological intervention, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are Rifapentine and isoniazid for 12 weeks trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rifapentine and isoniazid for 12 weeks clinical trials?
The Aurum Institute NPC (1) and Centers for Disease Control and Prevention (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rifapentine and isoniazid for 12 weeks works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rifapentine and isoniazid for 12 weeks works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rifapentine and isoniazid for 12 weeks (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.